An observational study in PET-CT, sponsored by Central Hospital, Nancy, France. Not yet recruiting. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-07-17.
Sponsored by Central Hospital, Nancy, France · Observational
Differentiating radiation necrosis from tumor progression in patients with brain metastases has a major therapeutic and prognostic implications
Differentiating radiation necrosis from tumor progression in patients with brain metastases treated with radiotherapy is a major challenge in post-treatment management, as the therapeutic and prognostic implications differ substantially depending on whether the lesion represents radiation necrosis (surveillance, anti-angiogenic therapy) or tumor progression (re-initiation of local or systemic treatment).
In addition to brain MRI, amino acid PET imaging, including both static and dynamic acquisitions, is a key diagnostic tool for this purpose.
However, the added value of dynamic acquisitions remains uncertain, and the available evidence is limited to small patient series.
Central Hospital, Nancy, France is the lead sponsor of 778 studies on the registry; 183 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All patients referred for amino acid PET imaging in the Nuclear Medicine Department of Nancy University Hospital for the differential diagnosis between radiation necrosis and brain tumor progression between November 1, 2018, and April 30, 2026.
Exclusion Criteria:
static and dynamic analyses
To compare the diagnostic performance amino acid PET imaging
Uptake of tumor
Time frame: Day 1
To evaluate the potential impact of immunotherapy administered before or during PET imaging
MRI results
Time frame: 2 weeks
No study locations are listed for this record.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Central Hospital, Nancy, France